<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell lines are heterogenous with regard to phenotype, growth characteristics, Epstein-Barr virus (EBV) latent gene and BCL-2 expression </plain></SENT>
<SENT sid="1" pm="."><plain>Previously we have demonstrated that transfection with the EBV genes LMP or EBNA-2 upregulates BCL-2 in B-cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>In order to test the functional relevance of these findings, cell lines were examined with regard to their sensitivity towards different <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing agents </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines transfected with LMP expressed high levels of BCL-2, and were compared with the parental cell line expressing little or no BCL-2 </plain></SENT>
<SENT sid="4" pm="."><plain>We also studied EBV immortalized lymphoblastoid cell lines (LCL) with high BCL-2 expression and strong resistance towards low serum concentrations </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="2" ids="17650">Hydrocortisone</z:chebi> (HC) and 2-chlorodeoxyadenosine (2-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e>) were used alone or in different combinations </plain></SENT>
<SENT sid="6" pm="."><plain>Cell growth and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> were studied morphologically and by determination of viability and DNA fragmentation </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines showed different sensitivity towards HC-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and sensitive cell lines became more resistant towards HC after <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> with EBV or transfection with LMP and subsequent upregulation of BCL-2 expression </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines and LCL were relatively insensitive towards 2-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and high concentrations of 2-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e> were necessary, independently of the levels of BCL-2 expression </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast to low-grade non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 2-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CDA</z:e> does not appear to be a valuable drug for the treatment of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>LMP expression provides resistance towards <z:chebi fb="2" ids="17650">hydrocortisone</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in vitro, possible through upregulation of BCL-2 </plain></SENT>
</text></document>